69 related articles for article (PubMed ID: 28393315)
21. Mechanisms of lapatinib resistance in HER2-driven breast cancer.
D'Amato V; Raimondo L; Formisano L; Giuliano M; De Placido S; Rosa R; Bianco R
Cancer Treat Rev; 2015 Dec; 41(10):877-83. PubMed ID: 26276735
[TBL] [Abstract][Full Text] [Related]
22. [Pharmacological profiles and clinical effects of lapatinib tosilate (Tykerb)].
Arai H; Yamaki M; Nishimura Y
Nihon Yakurigaku Zasshi; 2010 Sep; 136(3):175-84. PubMed ID: 20838021
[No Abstract] [Full Text] [Related]
23. Identification and characterization of biomarkers and their functions for Lapatinib-resistant breast cancer.
Zhang L; Huang Y; Zhuo W; Zhu Y; Zhu B; Chen Z
Med Oncol; 2017 May; 34(5):89. PubMed ID: 28393315
[TBL] [Abstract][Full Text] [Related]
24. Identifying differentially expressed genes and screening small molecule drugs for lapatinib-resistance of breast cancer by a bioinformatics strategy.
Zhuo WL; Zhang L; Xie QC; Zhu B; Chen ZT
Asian Pac J Cancer Prev; 2014; 15(24):10847-53. PubMed ID: 25605188
[TBL] [Abstract][Full Text] [Related]
25. Identification of novel therapeutic target genes in acquired lapatinib-resistant breast cancer by integrative meta-analysis.
Lee YS; Hwang SG; Kim JK; Park TH; Kim YR; Myeong HS; Choi JD; Kwon K; Jang CS; Ro YT; Noh YH; Kim SY
Tumour Biol; 2016 Feb; 37(2):2285-97. PubMed ID: 26361955
[TBL] [Abstract][Full Text] [Related]
26. Identification of breast cancer hub genes and analysis of prognostic values using integrated bioinformatics analysis.
Fang E; Zhang X
Cancer Biomark; 2017 Dec; 21(1):373-381. PubMed ID: 29081411
[TBL] [Abstract][Full Text] [Related]
27. Identification of prostate cancer hub genes and therapeutic agents using bioinformatics approach.
Fang E; Zhang X; Wang Q; Wang D
Cancer Biomark; 2017 Dec; 20(4):553-561. PubMed ID: 28800317
[TBL] [Abstract][Full Text] [Related]
28. Identification of differentially expressed genes regulated by molecular signature in breast cancer-associated fibroblasts by bioinformatics analysis.
Vastrad B; Vastrad C; Tengli A; Iliger S
Arch Gynecol Obstet; 2018 Jan; 297(1):161-183. PubMed ID: 29063236
[TBL] [Abstract][Full Text] [Related]
29. Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.
Kadera BE; Toste PA; Wu N; Li L; Nguyen AH; Dawson DW; Donahue TR
Clin Cancer Res; 2015 Jan; 21(1):157-65. PubMed ID: 25348515
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of cell uptake and toxicity of the anticancer drug cisplatin.
Eljack ND; Ma HY; Drucker J; Shen C; Hambley TW; New EJ; Friedrich T; Clarke RJ
Metallomics; 2014 Nov; 6(11):2126-33. PubMed ID: 25306996
[TBL] [Abstract][Full Text] [Related]
31. De-acetylation and degradation of HSPA5 is critical for E1A metastasis suppression in breast cancer cells.
Chang YW; Chen HA; Tseng CF; Hong CC; Ma JT; Hung MC; Wu CH; Huang MT; Su JL
Oncotarget; 2014 Nov; 5(21):10558-70. PubMed ID: 25301734
[TBL] [Abstract][Full Text] [Related]
32. Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.
Araki K; Fukada I; Horii R; Takahashi S; Akiyama F; Iwase T; Ito Y
Breast Cancer Res Treat; 2014 Nov; 148(1):197-209. PubMed ID: 25270122
[TBL] [Abstract][Full Text] [Related]
33. Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer.
Schroeder RL; Stevens CL; Sridhar J
Molecules; 2014 Sep; 19(9):15196-212. PubMed ID: 25251190
[TBL] [Abstract][Full Text] [Related]
34. Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer.
Creedon H; Byron A; Main J; Hayward L; Klinowska T; Brunton VG
Biochem Soc Trans; 2014 Aug; 42(4):822-30. PubMed ID: 25109964
[TBL] [Abstract][Full Text] [Related]
35. PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
McDermott MS; Browne BC; Conlon NT; O'Brien NA; Slamon DJ; Henry M; Meleady P; Clynes M; Dowling P; Crown J; O'Donovan N
Mol Cancer; 2014 Jun; 13():157. PubMed ID: 24958351
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
Formisano L; Nappi L; Rosa R; Marciano R; D'Amato C; D'Amato V; Damiano V; Raimondo L; Iommelli F; Scorziello A; Troncone G; Veneziani B; Parsons SJ; De Placido S; Bianco R
Breast Cancer Res; 2014 May; 16(3):R45. PubMed ID: 24887236
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
